Rhythm Pharmaceuticals Inc (RYTM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Rhythm Pharmaceuticals Inc   (NASDAQ: RYTM)


Rhythm Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Rhythm Pharmaceuticals Inc's ROI in the second quarter of 2026?
Rhythm Pharmaceuticals Inc recorded a cumulative net loss of $-210 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -55.53%.

Within the Healthcare sector 167 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2216 to 3769.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 44.86 % 18.77 % 20.09 % 0.56 % -14.15 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 408 336 371 399 240
Return On Investment (TTM) -55.53 % -61.79 % -63.07 % -66.89 % -72.1 %
RYTM's Overall Ranking # 3769 # 2216 # 2857 # 3585 # 3188
Seq. Investment Change TTM 12.55 % 5.07 % 8.3 % 13.12 % -7.73 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -210 -208 -202 -198 -188

RYTM Company Profile >> Back to RYTM Roi Comparisons >> See Annual RYTM Return On Investment



Return On Investment RYTM's Ranking
Within: No.
Industry # 56
Sector # 168
Overall # 3769

Return On Investment Statistics
High Average Low
-19.16 %
-58.45 %
-98.18 %
(Sep 30 2021)   (Dec 31 2024)



  News about Rhythm Pharmaceuticals Inc Return on Investment ROI

Rhythm Pharmaceuticals Grants Employment Inducement Equity to Stimulate Growth and Drive Innovation.

February 8, 2024

Rhythm Pharmaceuticals Grants Employment Inducement Equity to Drive Growth and Innovation
Summary:
Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced the issuance of employment inducement grants to new employees. These grants include stock options and restricted stock units, showing the company s commitment to attracting top talent and fostering innovation. The aim is to incentivize employees to contribute to the company s growth and further its mission of transforming the lives of patients affected by rare melanocortin-4 receptor pathway diseases

Rhythm Pharmaceuticals Empowers Growth and Innovation with Substantial Inducement Grants to New Talent

January 12, 2024


Rhythm Pharmaceuticals, a leading biopharmaceutical company dedicated to improving the lives of patients and families facing rare neuroendocrine diseases, recently announced the issuance of employment inducement grants to four highly skilled individuals. These grants, which comprise inducement stock options and restricted stock units (RSUs), signify the company s commitment to attracting top talent and fostering a culture of innovation. By offering these valuable incentives, Rhythm Pharmaceuticals aims to drive its growth trajectory and fulfill its mission of transforming the lives of patients affected by rare melanocortin-4 receptor pathway diseases.
On January 9, 2023, Rhythm Pharmaceuticals Compensation Committee, part of the company s esteemed board of directors, took the decision to award inducement equity grants, encompassing 13,020 shares of its common stock. These included inducement stock options enabling the purchase of 8,680 shares of common stock and RSUs covering 4,340 shares of the company s common stock. The inducement grants validate Rhythm Pharmaceuticals unwavering dedication to attracting and retaining top talent in order to drive growth and advance innovative solutions in the field of rare neuroendocrine diseases.





Financial Statements
Rhythm Pharmaceuticals Inc's II. Quarter Investments $ 408 Millions RYTM's Balance sheet
Rhythm Pharmaceuticals Inc's II. Quarter Income $ -50 Millions Quarterly RYTM's Income Statement
RYTM's Income by Division See RYTM's Income by Division


RYTM Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 371 273 382 342 284
Y / Y Investment Growth 35.96 % -28.65 % 11.8 % 20.36 % 68.06 %
Net Income in Millions -202 -265 -185 -181 -70
Y / Y Net Income Growth - - - - -
Annual Return On Investment -54.44 % -96.98 % -48.3 % -52.96 % -24.5 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RYTM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RYTM's Competitors
Subscribers only: Roi for Rhythm Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for RYTM's Customers

Other Ratios
RYTM's Roa RYTM's Inventory Turnover Ratio RYTM's Growth Rates RYTM's Dividend Statistics
RYTM's Profitability Ratios RYTM's Asset Turnover Ratio RYTM's Dividend Growth
RYTM's Roe RYTM's Valuation Ratios RYTM's Financial Strength Ratios RYTM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:37:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.